BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.